Yahoo Web Search

Search results

    • Tango terminates USP1 inhibitor programme

      Tango terminates USP1 inhibitor programme

      Clinical Trials Arena via Yahoo Finance· 2 days ago

      The company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...

    • What's the Goal in Treating Type 2 Diabetes?

      What's the Goal in Treating Type 2 Diabetes?

      Medscape· 3 days ago

      Anne Peters discusses the differences in the newly published American College of Physicians and the American Diabetes Association guidelines for treating...